Compare Natera Inc. Common Stock (NTRA) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while iShares 20 Plus Year Treasury Bond ETF trades at $80.02 (market cap $49.02B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| NTRA | TLT | |
|---|---|---|
Market Cap | $57.03B | $49.02B |
Volume | 1,131,157 | 50,953,748 |
Sector | Health | Fixed Income |
52-Week High | $425.64 | $92.06 |
52-Week Low | $179.42 | $77.11 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $78.34 with a slight 0.37% daily gain amid a challenging bond market environment. Technical indicators show a bearish trend with moving averages and oscillators signaling selling pressure, while fundamental metrics remain unavailable for this bond ETF. The fund has declined significantly, down 11% year-to-date and 46% over five years as Treasury yields reach multi-decade highs.
The outlook remains pressured by rising interest rates and inflation concerns, though recent yield retreats offer potential stabilization. Key risks include continued Fed hawkishness and economic data surprises, while opportunities exist for long-term investors seeking yield at current levels. Market sentiment is cautious as investors weigh duration exposure against persistent inflation pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
